Stifel Financial Corp Sells 20,258 Shares of Moderna, Inc. (NASDAQ:MRNA)

Stifel Financial Corp lowered its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 48.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,659 shares of the company's stock after selling 20,258 shares during the period. Stifel Financial Corp's holdings in Moderna were worth $901,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. abrdn plc raised its stake in shares of Moderna by 28.1% in the fourth quarter. abrdn plc now owns 315,912 shares of the company's stock worth $12,842,000 after purchasing an additional 69,360 shares during the last quarter. Spire Wealth Management raised its position in Moderna by 2,150.4% in the 4th quarter. Spire Wealth Management now owns 23,224 shares of the company's stock worth $966,000 after buying an additional 22,192 shares during the last quarter. Proficio Capital Partners LLC lifted its stake in Moderna by 4,418.9% during the 4th quarter. Proficio Capital Partners LLC now owns 147,360 shares of the company's stock valued at $6,127,000 after acquiring an additional 144,099 shares during the period. South Dakota Investment Council boosted its holdings in shares of Moderna by 4.0% during the 4th quarter. South Dakota Investment Council now owns 299,399 shares of the company's stock valued at $12,449,000 after acquiring an additional 11,500 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Moderna by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company's stock worth $300,219,000 after acquiring an additional 171,774 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on MRNA. The Goldman Sachs Group cut Moderna from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $99.00 to $51.00 in a research report on Wednesday, January 29th. Berenberg Bank boosted their target price on shares of Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a research report on Thursday, January 16th. JPMorgan Chase & Co. decreased their price target on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating on the stock in a research report on Friday, March 21st. Leerink Partners dropped their price target on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a research note on Thursday, January 16th. Finally, Citigroup started coverage on Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price objective for the company. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $53.95.

Moderna Trading Down 0.5 %

Shares of Moderna stock opened at $24.25 on Friday. The firm has a market cap of $9.38 billion, a PE ratio of -2.61 and a beta of 1.99. The stock has a 50 day moving average of $28.89 and a 200 day moving average of $36.57. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $170.47.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, topping analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The firm had revenue of $108.00 million for the quarter, compared to the consensus estimate of $130.35 million. During the same period in the previous year, the firm posted ($3.07) EPS. The business's quarterly revenue was down 35.3% on a year-over-year basis. As a group, equities research analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.